Benefit of Paraaortic Lymph Node Evaluation in Endometrioid Endometrial Carcinoma; A 10-year retrospective study in Thailand
Article Sidebar
Main Article Content
Abstract
Objectives: To evaluate 5-year survival in patients with endometrioid endometrial carcinoma, who underwent evaluation of retroperitoneal pelvic lymph nodes alone, compared to evaluation of pelvic with paraaortic lymph nodes.
Materials and Methods: This retrospective cohort study enrolled 636 women who were diagnosed with endometrioid endometrial carcinoma and underwent surgical staging at Faculty of Medicine Siriraj Hospital, Mahidol University between January 2006 and December 2015. Patients who underwent pelvic lymph node evaluation (n = 257) and pelvic with paraaortic lymph node evaluation (n = 379) were included.
Results: The median follow-up time was 60 months. The 5-year overall survival rate (OS) in the pelvic lymph node (PLN) and pelvic with paraaortic lymph node (PPALN) groups was 81.6% and 87.7%, respectively (p = 0.073). However, the PPALN group had significantly longer survival than the PLN group after adjustment for other prognostic factors (adjusted hazard ratio (HR)) 1.63 (1.06-2.52, p = 0.028)). There was a trend to improve 5-year disease-specific survival (DSS) for the European Society of Gynaecological Oncology (ESGO)/ European Society for Radiotherapy and Oncology (ESTRO)/ European Society of Pathology (ESP) high risk patients, who underwent PPALN evaluation (85.6%) compared with PLN evaluation (70.8%), p = 0.061.
Conclusion: In endometrioid endometrial carcinoma patients, the evaluation of pelvic and paraaortic lymph nodes is independently associated with enhanced survival outcomes. Therefore, in situations when a sentinel lymph node biopsy is not feasible, we suggest evaluating the pelvic and paraaortic lymph nodes for all patients diagnosed with endometrioid endometrial cancer.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30.
Observatory TGC. Thailand Source:Globocan 2020 [Available from: https://gco.iarc.fr/today/data/factsheets/populations/764-thailand-fact-sheets.pdf.
Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-7.
Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987;60(8 Suppl):2035-41.
Koskas M, Amant F, Mirza MR, Creutzberg CL. Cancer of the corpus uteri: 2021 update. Int J Gynaecol Obstet 2021;155 Suppl 1:45-60.
Coronado PJ, Rychlik A, Martinez-Maestre MA, Baquedano L, Fasero M, Garcia-Arreza A, et al. Role of lymphadenectomy in intermediate-risk endometrial cancer: a matched-pair study. J Gynecol Oncol 2018;29:e1.
Orr JW, Jr., Holloway RW, Orr PF, Holimon JL. Surgical staging of uterine cancer: an analysis of perioperative morbidity. Gynecol Oncol 1991;42: 209-16.
Larson DM, Johnson K, Olson KA. Pelvic and para-aortic lymphadenectomy for surgical staging of endometrial cancer: morbidity and mortality. Obstet Gynecol 1992;79:998-1001.
Hidaka T, Kato K, Yonezawa R, Shima T, Nakashima A, Nagira K, et al. Omission of lymphadenectomy is possible for low-risk corpus cancer. Eur J Surg Oncol 2007;33:86-90.
group As, Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009;373: 125-36.
Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 2008;100:1707-16.
Bassarak N, Blankenstein T, Bruning A, Dian D, Bergauer F, Friese K, et al. Is lymphadenectomy a prognostic marker in endometrioid adenocarcinoma of the human endometrium? BMC Cancer 2010;10:224.
Eggemann H, Ignatov T, Kaiser K, Burger E, Costa SD, Ignatov A. Survival advantage of lymphadenectomy in endometrial cancer. J Cancer Res Clin Oncol 2016;142:1051-60.
Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet 2010;375:1165-72.
Mariani A, Webb MJ, Keeney GL, Haddock MG, Calori G, Podratz KC. Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary? Am J Obstet Gynecol 2000;182:1506-19.
Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 2021;31:12-39.
Chang SJ, Kim WY, Yoon JH, Yoo SC, Chang KH, Ryu HS. Para-aortic lymphadenectomy improves survival in patients with intermediate to high-risk endometrial carcinoma. Acta Obstet Gynecol Scand 2008;87: 1361-9.
May T, Shoni M, Vitonis AF, Quick CM, Growdon WB, Muto MG. The role of para-aortic lymphadenectomy in the surgical staging of women with intermediate and high-risk endometrial adenocarcinomas. Int J Surg Oncol 2013;2013:858916.
Lutman CV, Havrilesky LJ, Cragun JM, Secord AA, Calingaert B, Berchuck A, et al. Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology. Gynecol Oncol 2006;102:92-7.
Tong SY, Lee JM, Lee JK, Kim JW, Cho CH, Kim SM, et al. Efficacy of para-aortic lymphadenectomy in early-stage endometrioid uterine corpus cancer. Ann Surg Oncol 2011;18:1425-30.
Toptas T, Simsek T. Survival analysis of pelvic lymphadenectomy alone versus combined pelvic and para-aortic lymphadenectomy in patients exhibiting endometrioid type endometrial cancer. Oncol Lett 2015;9:355-64.
Luomaranta A, Leminen A, Loukovaara M. Prediction of lymph node and distant metastasis in patients with endometrial carcinoma: a new model based on demographics, biochemical factors, and tumor histology. Gynecol Oncol 2013;129:28-32.
Volpi L, Sozzi G, Capozzi VA, Ricco M, Merisio C, Di Serio M, et al. Long term complications following pelvic and para-aortic lymphadenectomy for endometrial cancer, incidence and potential risk factors: a single institution experience. Int J Gynecol Cancer 2019;29:312-9.
Rossi EC, Kowalski LD, Scalici J, Cantrell L, Schuler K, Hanna RK, et al. A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol 2017;18: 384-92.
Watari H, Katayama H, Shibata T, Ushijima K, Satoh T, Onda T, et al. Phase III trial to confirm the superiority of pelvic and para-aortic lymphadenectomy to pelvic lymphadenectomy alone for endometrial cancer: Japan Clinical Oncology Group Study 1412 (SEPAL-P3). Jpn J Clin Oncol 2017;47:986-90.